CDK8 kinase--An emerging target in targeted cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cyclin-dependent kinase (CDK) inhibitors are investigated as anticancer agents, with nonselective compounds in clinical trials.
• CDK8 kinase plays crucial biological roles, offering a target for novel cancer therapeutics.
• Understanding CDK8's function provides a basis for developing targeted cancer treatments.

Purpose of the Study:

• To review the biological roles of CDK8 kinase in the context of cancer.
• To highlight the potential of CDK8 inhibitors as targeted anticancer therapeutics.
• To discuss structural aspects of CDK8 and its ligands for rational drug design.

Main Methods:

• Literature review of CDK8 kinase biology and inhibitors.
• Analysis of selective CDK8 inhibitors and their effects on cancer gene expression.
• Examination of structural features for drug design strategies.

Main Results:

• Several CDK8 inhibitors exhibit significant selectivity and effectiveness against cancer-specific gene expression programs.
• The biological roles of CDK8 support its utility as a therapeutic target in oncology.
• Rational drug design approaches considering CDK8 structure and ligands are advancing inhibitor development.

Conclusions:

• CDK8 kinase is a validated target for developing selective anticancer drugs.
• Targeted inhibition of CDK8 holds potential for future oncology therapies.
• Continued development of CDK8 inhibitors is expected to yield effective treatments for cancer.